Drugs /

212pb-dotamtate

Back to Drugs List

Overview

Trade Name(s):
Alphamedix

Clinical Trials

View Clinical Trials for 212pb-dotamtate

212pb-dotamtate has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating 212pb-dotamtate, 1 is phase 1 (1 open).

SSTR1 Expression, SSTR2 Expression, and SSTR3 Expression are the most frequent biomarker inclusion criteria for 212pb-dotamtate clinical trials.

Neuroendocrine tumor is the most common disease being investigated in 212pb-dotamtate clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating 212pb-Dotamtate
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating 212pb-dotamtate and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
AlphaMedix
Drug Target(s) [2]:
SSTR1, SSTR2, SSTR3, SSTR4, SSTR5

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.